The post reports that the SPDR S&P Biotech ETF (XBI) rose 17.27% in the month ending July 1, 2026, and it does not own any Nvidia shares, highlighting biotech's recent strength.

Dassault Systèmes is in talks to acquire a drug trial software company for approximately $2 billion, according to the Financial Times.

A Senate bill aims to reduce US reliance on China in the drug industry.

Chinese domestic futures closed mixed overnight, with PTA down over 2%, synthetic rubber up over 1%, and plastic and soybean meal up nearly 1%.

USTR Greer stated a preference for trade deals over 301 probes regarding drug pricing.

The article questions whether AI can develop better drugs given Wall Street's short-term timeline, posing the question of whether investors should pay up for the technology.

A market strategist says slumping AI stocks could signal strong buying momentum in healthcare, industrial, biotech, insurance and utility sectors.

A major drugmaker lost $27 billion in market value after a heart disease drug failed its Phase III trial.

A Bloomberg Television interview with Paul Weiss M&A co-head notes that biotech dealmaking in 2026 has hit a torrid pace, with more deals over $1 billion already this year than in all of 2025.

A Wall Street technician on CNBC states that financials, industrials, and biotech are poised for breakouts as tech leadership fades.

Roche chairman accuses US government of drug price 'blackmail' and warns of negative long-term impact on Europe.